So if I read this right, this Friday the index will be finalized. I am assuming that this will happen at the close of business and the rebalancing trades will happen on the next business day or Monday June 1. So the timing of my thesis is correct, we just have to wait and see how the rebalancing effects OMER.
6.0 / Rebalancing
6.1 / Procedure
The Index family is rebalanced quarterly in February, May, August, and November of each year. The Index component stocks are
determined two business days prior to the last Friday in the quarterly review using a proprietary quantitative model. The
quantitative model assigns a relative ranking to each stock in the universe of eligible companies, a “model score”. The new Index
component stocks are selected from the most highly ranked stocks within each sector and market capitalization group to control
the exposure of the Index to these segments of the market.
The share weight (rounded to the nearest whole share) assigned to each component stock in the new Index portfolio is determined
on the last Friday of the quarterly review month, so that each company included in the Index represents its assigned weighting as
determined based on its sector and market capitalization grouping. If the last Friday in the month of the quarterly review is an
Exchange Holiday, the first business day prior to that day will be used.
The new Index components and their share weights are announced publicly prior to taking effect after the close of trading on the
second business day following the last Friday in the quarterly review month. The share weight of each component stock in the
Index portfolio remains fixed between quarterly reviews except in the event of certain types of corporate actions such as stock
splits, reverse stock splits, stock dividends, or similar events. The share weights used in the Index calculation are not typically
adjusted for shares issued or repurchased between quarterly reviews. However, in the event of a merger between two Index
components, the share weight of the surviving entity may be adjusted to account for any stock issued in the acquisition.
If an Index component is not the surviving entity of a merger, acquisition, or similar corporate action, then that component is
deleted from the Index and t
Next Monday in my posted meant June 1. I have never really understand why "next" or "this" Monday can't be used interchangeably. When OMER was added to this fund in February the trades and volume spike happened on March 2 & 3.
You are off on your dates on your thesis even if it is true. From the Powers Shares Dynamic Pharmaceuticals Portfolio site and I quote... "The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November." IF it is happening it will have happened by June 1st.
that is good to know. I thought news was leaking on Huntington trial. Was updated last month at USclinicaltrial. I do not know what was changed. I looked at the dosage and did not see high dosage not sure why they would place a hold of medium dosage. Or the work completed by New York State Psychiatric Institute waiting on results. Or why the results for Schizophrenia have not been posted are they going to release them soon.
Possible. I think we will be fine, if the prices are low there will be no supply. If the prices are low R&D spending will be cut by companies. It is up to society as a whole to decide how they want the drug development to proceed. The wealth in EU do and can travel to the US for treatment. New drugs and healthcare development over the decades have helped reduce healthcare costs by cutting stays short, avoiding complications and allowing people to live their lives as they want versus making changes to their diet and exercising. Lots of outpatient surgeries where in the past it would require days of inpatient stay.
This is my trading thesis for the next week. Omeros will be removed from the PowerShares Dynamic Pharmaceuticals Portfolio and over 3 million shares will be sold next Monday and Tuesday. On March 2 & 3 when Omeros was added to this fund the stock went from $20.87 to over $25 and over 7 millions shares were traded. I think that the smart shorts who know how this fund selects stocks are betting that it will be removed from the fund and that is why the short position has been increasing recently. As the price is driven down by the fund's sale of shares the shorts will then cover their shorts without an increase in the share price.
I have some cash on hand and my goal is to be prepared to buy some more Omeros if my thesis happens. I think I will need to be nimble and a little lucky as the stock price could be very volatile next Monday and/or Tuesday. If I am right, maybe I can pick up some more shares on the cheap and if I am wrong no harm as I am already long and one of my short term concerns disappears.
There is an article from Reuter titled Greece owes drugmakers $1.2 billion - and counting. One interesting tidbit. Drugmakers want any emergency programme to include steps to mitigate spillover effects on other markets, including curbs on re-exports of drugs and a block on other governments referencing Greek prices when setting their own drug prices.
Although Greece represents less than 1 percent of world drugs sales, it can have a bigger impact because of such reference pricing -- and the effect could be dramatic if it left the euro and prices in euro terms fell sharply.
I have not followed EU approvals before, would be nice to see what they mean by "proposed...administered" and "detailed recommendations" will mean when the drug is available.
It is proposed that Omidria is administered in a controlled surgical setting by a qualified ophthalmological surgeon experienced in intraocular lens replacement surgery.
Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion
Germany has said it has a deal to buy Sovaldi at #$%$41,000 for a 12-week course. That is deeply discounted from the initial price of #$%$56,500 with which the company started.
France--Twelve weeks of treatment will now cost 41,000 euros ($51,373) before tax, against 56,000 euros previously.
Omidria's status with the CHMP was likely expected and so there may be a slight buy on rumor/sell on news factor. OMER is successfully executing their plan and that's what we have to focus on pending substantive sales. It was nice for the PR to mention that OMER has six additional products in clinical development. The value going forward is the pipeline of products that OMER is building.
Today's news is great but IMO it would be quite premature for OMER to announce specific partner info before they get the formal approval in July.
Anyone have knowledge of when companies can announce a partner in EU , Can they before the 67 days before EU decision ?
Sentiment: Strong Buy
Was there much price difference between the major EU countries like Germany, France and United Kingdom?
tc16 I think we all want to know the profit amount per sale. Some of the EU nations have a lower cost of business. The cost of omidira may be low and the majority of the cost deals with the selling staff. On the Q1 test launch sales of 238 had a cost of 11. Omeros signed with Hospira Italy and if produced in Italy the cost would be higher versus some of the lower cost EU nations but there still is a lot of room to make a profit. The sales staff in the lower cost EU nations will have sales staff earning a lower wage versus US, Italy and other high cost of living EU nations.
I own and follow GILD and have watched the EU adoption of their hep C products. My guess is to expect about 60-75% pricing say $300 - 350 per vial. With the partnership cost the net might be $150 per vial. Just my guess on this as pricing will play out country by country. Next up should be Japan if they are moving forward.